Drug Trial Radar · NCT05775289
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
182
Actual
Start
Mar 15, 2023
Primary completion
Jun 20, 2024
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in participants with previously untreated, locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) non-small-cell lung cancer (NSCLC) who are not eligible to receive curative surgery and/or definitive chemoradiotherapy.
Conditions
- Non-small Cell Lung Cancer
Interventions
TobemstomigDrug
Participants will receive intravenous (IV) tobemstomig for four 21-day cycles
PembrolizumabDrug
Participants will receive IV pembrolizumab four 21-day cycles
PaclitaxelDrug
Participants will receive IV paclitaxel Q3W for four 21-day cycles
PemetrexedDrug
Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity
CarboplatinDrug
Participants will receive IV carboplatin Q3W for four 21-day cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Randomization to date of first documented disease progression or death (up to approximately 15 months)
- Objective Response Rate (ORR)Time frame: Up to approximately 15 months
Locations
50 sites in 11 countries. Site status is shown where the registry gives one.
Henry Ford Health System
Detroit, Michigan
Renown Regional Medical Center Hospital
Reno, Nevada
Westmead Hospital
Westmead, New South Wales, Australia
Lyell McEwin Hospital
Adelaide, South Australia, Australia
Barwon Health
Geelong, Victoria, Australia
Monash Health
Melbourne, Victoria, Australia
UZ Brussel
Brussels, Belgium
Jessa Zkh (Campus Virga Jesse)
Hasselt, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
AZ St Maarten Campus Leopoldstr
Mechelen, Belgium
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
Nucleo de Oncologia da Bahia - NOB
Salvador, Bahia, Estado de Bahia, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clínicas de Porto Alegre X
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil
Centre Leon Berard
Lyon, France
Hopital Cochin
Paris, France
Ico Rene Gauducheau
Saint-Herblain, France
CHU de Toulouse - Hôpital Larrey
Toulouse, France
Uniklinik Essen
Essen, Germany
LungenClinic Großhansdorf GmbH
Großhansdorf, Germany
Krankenhaus Martha-Maria Halle-Doelau
Halle, Germany
Thoraxklinik Heidelberg gGmbH
Heidelberg, Germany
Lungenfachklinik Immenhausen
Immenhausen, Germany
Azienda Ospedaliera San Giuseppe Moscati
Avellino, Campania, Italy
AZ.Osp S. Orsola ? Malpighi-Reparto di Oncologia Medica
Bologna, Emilia-Romagna, Italy
Policlinico Universitario "Agostino Gemelli"
Rome, Lazio, Italy
IRCCS AOU San Martino - IST
Genoa, Liguria, Italy
Irccs Istituto Europeo di Oncologia (IEO)
Milan, Lombardy, Italy
Asst Di Monza
Monza, Lombardy, Italy
IOV - Istituto Oncologico Veneto - IRCCS
Padova, Veneto, Italy
Instituto Nacional de Cancerologia
Distrito Federal, Mexico
ONCARE Viaducto Napoles
Mexico City, Mexico CITY (federal District), Mexico
AMIISTO Atencion Medica Integral Investigacion y Terapia Oncologica S.A de C.V
Mexico City, Mexico CITY (federal District), Mexico
Pusan National University Hospital
Busan, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.